newsfilter
← Latest News
GlobeNewswire·

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

Global pivotal program initiation on track for 2026Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent